Catherine D. DeAngelis leaves JAMA

The editorial describing her time at the journal is here. If you have access to the full version, watch out for the very big punch near the end. A visionary, or provoking deliberate change? Only time will tell. Still, it is very nice to see that she is leaving in the same fashion as she … Continue reading Catherine D. DeAngelis leaves JAMA

More aggressive marketing ∝ 1/benefit-to-harm ratio

New “Law” Attempts to Explain Strategies Drug Marketers Use to Sway Prescribing, March 16, 2011, Mitka 305 (11): 1083 — JAMA An interesting and concise new article on the influence of marketing on prescribing patterns was published online in the American Journal of Public Health and then picked up in the commentary of JAMA. It … Continue reading More aggressive marketing ∝ 1/benefit-to-harm ratio

Another approved drug may leave the market

Bevacizumab Treatment for Solid Tumors, February 2, 2011, Hayes 305 (5): 506 — JAMA Avastin is a really expensive (think 50K a year) and dangerous (people die more often) drug that has been shown to have marginal positive effects on the progression of cancer for some patients. It is a very difficult question to weigh … Continue reading Another approved drug may leave the market